Boehringer Ingelheim Corporation Release: New Data Demonstrate Sustained Glucose Reduction and Weight Loss Up to 90 Weeks With Investigational SGLT-2 Inhibitor, Empagliflozin*
Published: Jun 11, 2012
INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US & UK. Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) presented study results that showed the investigational SGLT-2 inhibitor empagliflozin*, alone or as an add-on to metformin, reduced haemoglobin A1c (HbA1c) levels, fasting plasma glucose (FPG) and body weight when given to adults with type 2 diabetes for up to 90 weeks.1 HbA1c is an index of blood glucose control for the previous two to three months. The new data, from a Phase IIb open-label extension study, were presented as a late-breaking abstract at ADA.